0 11

Cited 0 times in

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Authors
 Joaquin Mateo  ;  Gopinath Ganji  ;  Charlotte Lemech  ;  Howard A. Burris  ;  Sae-Won Han  ;  Karen Swales  ;  Shaun Decordova  ;  M. Phillip DeYoung  ;  Deborah A. Smith  ;  Shanker Kalyana-Sundaram  ;  Jiuhua Wu  ;  Monica Motwani  ;  Rakesh Kumar  ;  Jerry M. Tolson  ;  Sun Young Rha  ;  Hyun Cheol Chung  ;  Joseph P. Eder  ;  Sunil Sharma  ;  Yung-Jue Bang  ;  Jeffrey R. Infante  ;  Li Yan  ;  Johann S. de Bono  ;  Hendrik-Tobias Arkenau 
Citation
 Clinical Cancer Research, Vol.23(19) : 5981-5992, 2017 
Journal Title
 Clinical Cancer Research 
ISSN
 1078-0432 
Issue Date
2017
Abstract
Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target effects of pan-PI3K inhibitors. GSK2636771 is a potent, orally bioavailable, adenosine triphosphate-competitive, selective inhibitor of PI3Kβ.Methods: We evaluated the safety, pharmacokinetics, pharmacodynamics and antitumor activity of GSK2636771 to define the recommended phase II dose (RP2D). During the dose-selection and dose-escalation stages (parts 1 and 2), patients with PTEN-deficient advanced solid tumors received escalating doses of GSK2636771 (25-500 mg once daily) using a modified 3+3 design to determine the RP2D; tumor type-specific expansion cohorts (part 3) were implemented to further assess tumor responses at the RP2D.Results: A total of 65 patients were enrolled; dose-limiting toxicities were hypophosphatemia and hypocalcemia. Adverse events included diarrhea (48%), nausea (40%), and vomiting (31%). Single- and repeat-dose exposure increased generally dose proportionally. GSK2636771 400 mg once daily was the RP2D. Phospho/total AKT ratio decreased with GSK2636771 in tumor and surrogate tissue. A castrate-resistant prostate cancer (CRPC) patient harboring PIK3CB amplification had a partial response for over a year; an additional 10 patients derived durable (≥24 weeks) clinical benefit, including two other patients with CRPC with PIK3CB alterations (≥34 weeks). GSK2636771 400 mg once daily orally induced sufficient exposure and target inhibition with a manageable safety profile.Conclusions: Genomic aberrations of PIK3CB may be associated with clinical benefit from GSK2636771.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/161400
DOI
10.1158/1078-0432.CCR-17-0725
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
라선영(Rha, Sun Young) ; 정현철(Chung, Hyun Cheol)
사서에게 알리기
  feedback
Full Text
http://clincancerres.aacrjournals.org/content/23/19/5981.long
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse